Ibudilast: A review of its pharmacology, efficacy and safety in respiratory and neurological disease

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2897-2904

  Rolan, P ^a   Hutchinson, M R ^a   Johnson, K W ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Avigen Inc   (United States)

Author keywords

Glia; Ibudilast; Multiple sclerosis; Neuropathic pain; Priming

Indexed keywords

IBUDILAST; METFORMIN; OPIATE; PHOSPHODIESTERASE INHIBITOR; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APATHY; ASTHMA; BILIRUBIN BLOOD LEVEL; CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GLIA CELL; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INSOMNIA; JAPAN; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; POSTSTROKE DIZZINESS; PRURITUS; RASH; REINFORCEMENT; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; REWARD; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THROMBOCYTOPENIA; TREMOR; VOMITING; WITHDRAWAL SYNDROME;

BRONCHODILATOR AGENTS; HUMANS; NERVOUS SYSTEM DISEASES; PYRIDINES; RESPIRATORY TRACT DISEASES;

EID: 73149087272     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903426189     Document Type: Review

References (43)

1. Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 2009;157:892-906
2. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007;10:1355-1360
3. Milligan E, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23-26
4. Romero-Sandoval EA, Horvath RJ, DeLeo JA. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Invest Drugs 2008;9:726-734
5. Huang Z, Liu S, Zhang L, et al. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci 2006;78:2663-2668
6. Gibson L, Hastings S, McPhee I, et al. The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006;538:39-42
7. Ohashi M, Uno T, Nishino K. Effect of ibudilast, a novel antiasthmatic agent, on anaphylactic bronchoconstriction: predominant involvement of endogenous slow reacting substance of anaphylaxis. Int Arch Allergy Immunol 1993;101:288-296
8. Ohtsu H, Fujimoto Y, Yamauchi K, et al. Pharmacological effect of KC-404 on leukotriene release from human leukocytes induced by ionophore A23187. Int Arch Allergy Appl Immunol 1989;89:306-310
9. Feng J, Misu T, Fujihara, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004;10:494-498
10. Choi SH, Sakamoto T, Fukutomi O, et al. Pharmacological study of phospholipase A2-induced histamine release from rat peritoneal mast cells. J Pharmacobiodyn 1989;12:517-522
11. Souness JE, Villamil ME, Scott LC, et al. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br J Pharmacol 1994;111:1081-1088
12. Chihara J, Urayama O, Kayaba H, et al. Inhibitory effect of ibudilast (KC-404) on the expression of the beta2 integrin family on an eosinophilic cell line (EoL-1). Ann Allergy Asthma Immunol 1998;81:448-450
13. Kawasaki A, Osaki R, Mizushima Y, et al. A novel antiasthmatic agent on airway hypersensitivity in bronchial asthma. J Asthma 1992;29:245-252
14. Yoshioka A, Yamaya Y, Saiki S, et al. Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line. J Neurochem 2000;74:633-640
15. Yoshioka A, Shimizu Y, Hirose G, et al. Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J Neurochem 1998;70:2416-2423
16. Takuma K, Lee E, Enomoto R, et al. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol 2001;133:841-848
17. Mizuno T, Kurotani T, Komatsu Y, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004;46:404-411
18. Ledeboer A, Hutchinson MR, Watkins LR, et al. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007;16:935-950
19. Suzumura A, Ito A, Yoshikawa M, et al. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999;837:203-212
20. Fujimoto T, Sakoda S, Fujimura H, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999;95:35-42
21. Cho Y, Lolis E. AV411 (ibudilast) and AV1013 are allosteric inhibitors of macrophage migration inhibitory factor: enzymatic, functional, and structural studies. Manuscript submitted, Nat Chem Bio
22. Wakita H, Tomimoto H, Akiguchi I, et al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res 2003;992:53-59
23. Kagitani-Shimono K, Mohri I, Fujitani Y, et al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation 2005;2:10-22
24. Ladecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007;10:1369-1376
25. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23-36
26. Ledeboer A, Liu T, Shumilla JA, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2007;2:279-291
27. Ellis AL,Wieseler J, Ramos K, et al. A novel model of spinal cord injury: characterization of exaggerated pain behavior and glial activation Program No. 171.22. 2008; NeuroscienceMeeting Planner.Washington, DC: Society for Neuroscience, 2008. Available from http://www.abstractsonline. com/Plan/ViewSession.aspx?sKey=9f0145ff-534c4a96-9cab-0df88ee864dc
28. Dafny N, Dougherty PM, Drath D. Immunosuppressive agent modulates the severity of opiate withdrawal. NIDA Res Monogr 1990;105:553-555
29. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001;39:281-286
30. Hutchinson MR, Bland ST, Johnson KW, et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 2007;7:98-111
31. Hutchinson MR, Coats BD, Lewis SS, et al. Proinflammatory cytokines oppose opioid induced acute and chronic analgesia. Brain Behav Immun 2008;22:1178-1189
32. Hutchinson MR, Lewis SS, Coats BD, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009;23:240-250
33. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2009. 11 Aug 2009 [Epub ahead of print]
34. Bonci A, Bernardi G, Grillner P, et al. The dopamine-containing neuron; maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 2003;24:172-177
35. Bland ST, Hutchinson MR, Maier SF, et al. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun 2009;23:492-497
36. Takagi K, Endo K, Nagatsu Y. Research relating to pharmacokinetics of 3-Isobutyryl-2-Isopropylpyrazolo[1,5a] Pyridine (KC-404) (Report No. 1): absorption, distribution and excretion in rats, dogs and monkeys. Appl Pharmacol (Japan) 1985;30:967-981
37. Nagatsu Y, Higuchi T, Hirobe M. Application of chemical P-450 model systems to study drug metabolism. III. Metabolism of 3-isobutyryl-2- isopropylprazolo [1,5-alpha]pyridine. Chem Pharm Bull (Tokyo) 1990;38:400-403
38. Sanftner L, Gibbons J, Gross M, et al. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica 2009. [Epub ahead of print]
39. Rolan P, Gibbons JA, He L, et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol 2008;66:792-801
40. Shida T, Kawakami Y, Mue S, et al. Clinical studies of KC-404 for treatment of adult bronchial asthma. Evaluation by multi-institution open trial. Kiso to Rinsho 1985;19:65-81
41. Sone H, Okuda Y, Asakura Y, et al. Efficacy of ibudilast on lower limb circulation of diabetic patients with minimally impaired baseline flow: a study using color Doppler ultrasonography and laser Doppler flowmetry. Angiology 1995;46:699-703
42. Inoue N, Harada M. Effect of ibudilast on non-specific symptoms in patients with chronic cerebral ischemia. Analysis of cerebral blood flow. Zrzeneimittelforschung 2008;58:277-282
43. Rolan P. Methods for targeting glial activation in the treatment of patients with chronic pain. Presented at the Mechanisms and Treatment of Neuropathic Pain Annual Meeting. Snowbird, Utah, USA, Nov 2007